-
Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock
Thursday, June 28, 2018 - 2:42pm | 455The biotechnology sector remains highly competitive, and investors willing to take on a stock with a high-risk, high-growth profile may want to consider Gilead Sciences, Inc. (NASDAQ: GILD), according to Raymond James. The Analyst Raymond James' Steven Seedhouse initiated coverage of...
-
Analyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher
Wednesday, December 13, 2017 - 11:24am | 422Bluebird bio Inc (NASDAQ: BLUE)'s stock has soared more than 200 percent since the start of 2017, with notable strength coming after the company released impressive data results at the American Society of Hematology conference. The Analyst Maxim Group's Jason McCarthy downgraded bluebird...